JOURNAL CLUB · ARTICLE OF THE WEEK
Early detection and treatment of obstructive sleep apnoea in infants with Down syndrome
Fauroux B, Sacco S, Couloigner V, et al. The Lancet Regional Health - Europe. 2024;45:101035. A prospective, non-randomised, controlled interventional study.
IN DOWN
SYNDROME
Better neurodevelopment with screening
Griffiths III subscores and secondary endpoints favoured the Screened Group over standard care.
Lower apnoea burden
Median AHI at 36 months was 1.0 (screened) vs 4.0 events/hour (standard care) - p=0.006.
Less moderate / severe OSA
Moderate and severe OSA were more common in the Standard Care Group.
Supportive, not definitive
Non-randomised, small (80 infants) and single-country - it points the way rather than proving it.
WHY THIS MATTERS
- OSA is very common in Down syndrome and often starts in infancy
- Untreated OSA is linked to neurocognitive and behavioural harm
- Standard guidance screens later (around age 3-4) - this asks whether earlier is better
- Infants cannot report symptoms, so OSA is easily missed
- Supports a proactive, early sleep-screening approach in Down syndrome
STRENGTHS
- Prospective, controlled design with objective polysomnography
- Serial 6-monthly sleep studies in the screened group
- Follow-up to 36 months with a standardised neurodevelopmental tool
- Tackles a common, under-recognised problem
- Consistent direction across primary and secondary endpoints
LIMITATIONS
- Non-randomised - groups may differ in unmeasured ways
- Small (80 infants) and single-country (France)
- 6-monthly polysomnography is resource-intensive and hard to deliver everywhere
- Primary-endpoint differences were supportive rather than clearly significant
- Cost-effectiveness and generalisability need confirming
Practice implications
OSA is common in children with Down syndrome and can begin in infancy, where it is easily missed and may harm the developing brain. This study suggests early, systematic sleep screening from 6 months - and treating any OSA found - lowers the apnoea burden and supports better neurocognitive outcomes at 3 years. It strengthens the case for a low threshold to assess sleep and breathing in babies with Down syndrome, and for keeping sleep on the list of associations you actively screen. Australian practice still leans on later, symptom-prompted assessment - a reason to watch how guidance evolves.
Would this change when you screen for OSA in a baby with Down syndrome?
How feasible is 6-monthly polysomnography where you work, and what are the alternatives?
How might untreated OSA in infancy harm neurodevelopment?
Does a non-randomised study like this justify changing practice, or do we need an RCT?
Lancet Reg Health Eur 2024 TRISOMY 21
The Hub condition page DOWN SYNDROME AUSTRALIA
Family information AAP GUIDANCE
Down syndrome health supervision
Take-home message: Obstructive sleep apnoea is common in infants with Down syndrome, easily missed, and linked to worse neurodevelopment. In this controlled study, early systematic sleep screening from 6 months of age - with treatment of any OSA found - lowered the apnoea-hypopnoea index and supported better neurocognitive outcomes at 3 years than standard care. It makes a strong case for thinking about sleep early in babies with Down syndrome. It is non-randomised and small, so needs confirmation, but the direction is clear.
For educational purposes only. Journal club appraisal - figures paraphrased from the published study; read the full article for complete data. Always align practice to current local guidelines.